Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

KKR-backed acquisition vehicel reiterates its bid for Assura

(Sharecast News) - An acquisition vehicle by KKR and Stonepeak reiterated its offer for Assura on Monday, dismissing the proposed alternative share-and-cash offer from Primary Health Properties (PHP), arguing it posed material financial and strategic risks. In a statement responding to PHP's 16 May proposal, Bidco reiterated that its own recommended all-cash offer, announced on 9 April, was the only proposal that would allow Assura shareholders to fully realise their investment while ensuring long-term growth through fresh capital deployment into UK healthcare infrastructure.

Bidco criticised PHP's offer for significantly increasing leverage to 55% loan-to-value, above sector norms and both companies' target ranges.

It warned that PHP's proposed asset disposals to reduce debt could result in value destruction and potentially erase the EPS gains it claimed.

Bidco also flagged heightened regulatory risk from potential Competition and Markets Authority scrutiny and expressed concern that PHP's funding plan could raise borrowing costs, jeopardise investment grade ratings, and severely constrain future growth.

Bidco concluded that its own proposal avoided those risks, and would provide Assura with stable, long-term private capital to support expansion without asset sales or deleveraging pressure.

At 0837 BST, shares in Assura were down 0.32% at 49,46p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.